| Reaction Details |
|---|
 | Report a problem with these data |
| Target | Mu-type opioid receptor |
|---|
| Ligand | BDBM50209671 |
|---|
| Substrate/Competitor | n/a |
|---|
| Meas. Tech. | ChEMBL_434340 (CHEMBL919398) |
|---|
| Ki | 0.460000±n/a nM |
|---|
| Citation |  Peng, X; Knapp, BI; Bidlack, JM; Neumeyer, JL Pharmacological properties of bivalent ligands containing butorphan linked to nalbuphine, naltrexone, and naloxone at mu, delta, and kappa opioid receptors. J Med Chem50:2254-8 (2007) [PubMed] Article |
|---|
| More Info.: | Get all data from this article, Assay Method |
|---|
| |
| Mu-type opioid receptor |
|---|
| Name: | Mu-type opioid receptor |
|---|
| Synonyms: | M-OR-1 | MOP | MOR-1 | MOR1 | MUOR1 | Mu Opioid Receptor | Mu opiate receptor | OPIATE Mu | OPRM1 | OPRM_HUMAN | hMOP | mu-type opioid receptor isoform MOR-1 |
|---|
| Type: | G Protein-Coupled Receptor (GPCR) |
|---|
| Mol. Mass.: | 44789.51 |
|---|
| Organism: | Homo sapiens (Human) |
|---|
| Description: | P35372 |
|---|
| Residue: | 400 |
|---|
| Sequence: | MDSSAAPTNASNCTDALAYSSCSPAPSPGSWVNLSHLDGNLSDPCGPNRTDLGGRDSLCP
PTGSPSMITAITIMALYSIVCVVGLFGNFLVMYVIVRYTKMKTATNIYIFNLALADALAT
STLPFQSVNYLMGTWPFGTILCKIVISIDYYNMFTSIFTLCTMSVDRYIAVCHPVKALDF
RTPRNAKIINVCNWILSSAIGLPVMFMATTKYRQGSIDCTLTFSHPTWYWENLLKICVFI
FAFIMPVLIITVCYGLMILRLKSVRMLSGSKEKDRNLRRITRMVLVVVAVFIVCWTPIHI
YVIIKALVTIPETTFQTVSWHFCIALGYTNSCLNPVLYAFLDENFKRCFREFCIPTSSNI
EQQNSTRIRQNTRDHPSTANTVDRTNHQLENLEAETAPLP
|
|
|
|---|
| BDBM50209671 |
|---|
| n/a |
|---|
| Name | BDBM50209671 |
|---|
| Synonyms: | (5alpha,6alpha)-17-(cyclobutylmethyl)-6,14-dihydroxy-4,5-epoxymorphinan-3-yl-17-(cyclobutylmethyl)morphinan-3-yl sebacoylate | CHEMBL224671 |
|---|
| Type | Small organic molecule |
|---|
| Emp. Form. | C52H70N2O7 |
|---|
| Mol. Mass. | 835.1214 |
|---|
| SMILES | O[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(OC(=O)CCCCCCCCC(=O)Oc5ccc6C[C@@H]7C8CCCC[C@]8(CCN7CC7CCC7)c6c5)c5O[C@@H]1[C@]2(CCN3CC1CCC1)c45 |TLB:41:40:29.46.30:32| |
|---|
| Structure | 
|
|---|
Search and Browse
